Announcements Trials

Browse Landscape

Phase

Status

Unknown 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 HER2-positive Breast Cancer 6 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Rare Tumor 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 4 trastuzumab deruxtecan 2 elacestrant 2 Vinorelbine 2 toripalimab 1 talazoparib 1 ribociclib 1 pyrotinib 1 palbociclib 1 olaparib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 apatinib 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 Radiotherapy 1 RAD1901 1 Letrozole 1 Itraconazole 1 Injections 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Capecitabine 1 Aromatase Inhibitors 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1 AZD9833 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Advanced Breast Cancer × pyrotinib × Clear all

NCT07180082 2025-11-18

CORIN-PYRA

RenJi Hospital

Phase 2 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡